

## Engagement Report for Clinical Commissioning Policies

<b>Unique Reference Number</b>	1601
<b>Policy Title</b>	Bortezomib for Relapsed/ Refractory Waldenstrom's Macroglobulinaemia
<b>Lead Commissioner</b>	Gabriel Lawson
<b>Clinical Reference Group</b>	Chemotherapy
Which stakeholders were contacted to be involved in policy development?	<p>A policy working group was established as per NHS England policy, clinical and PPV reps were members of the chemotherapy CRG.</p> <p>All CRG members and registered stakeholders were sent copies of the draft policy documents for comment.</p>
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	<p>All of the relevant Royal Colleges and professional societies have membership on the CRG. These include:</p> <ul style="list-style-type: none"> <li>British Oncology Pharmacy Association</li> <li>Royal College of Pathologists</li> <li>British Society for Haematology</li> </ul> <p>A representative for each group was sent all policy documents and given the opportunity to comment.</p>
Which stakeholders have actually been involved?	CRG members and a response from six registered stakeholders regarding draft documents
Explain reason if there is any difference from previous question	N/A
Identify any	N/A

<p>particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?</p>	
<p>How have stakeholders been involved? What engagement methods have been used?</p>	<p>As per policy development process all CRG members and CRG registered stakeholders have been sent draft policy documents for comment.</p>
<p>What has happened or changed as a result of their input?</p>	<p>No changes have been made to the policy proposition.</p> <p>While stakeholders submitted new evidence they felt was appropriate, this evidence was only relevant to first-line treatment whereas the policy deals with relapsed/refractory disease. The responses disagreed with the weighting of evidence by clinical panel but acknowledged that the evidence currently available is lacking. Several stakeholders noted that the patent for bortezomib expires next year, but the decision to not routinely commission was not made on grounds of cost. The decision for not routine commissioning has therefore not changed.</p>
<p>How are stakeholders being kept informed of progress with policy development as a result of their input?</p>	<p>Communication will be according to NHS England policy development process.</p>
<p>What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder</p>	<p>The CRG recommends 30 days public consultation based on the level of stakeholder response and the nature of the policy.</p>

involvement?	
--------------	--